EU/3/14/1400: Orphan designation for the treatment of neurotrophic keratitis
Table of contents
On 16 December 2014, orphan designation (EU/3/14/1400) was granted by the European Commission to MIMETECH S.r.l., Italy, for (1S,4R,5R,7S)-3,4-dibenzyl-2-oxo-6,8-dioxa-3-azabyciclo[3.2.1]octane-7-carboxylic acid-L-lysine for the treatment of neurotrophic keratitis.
The sponsorship was transferred to Orphan Europe SARL, France, in May 2018.
Treatment of neurotrophic keratitis
|Orphan designation status||
|EU designation number||
|Date of designation||
Orphan Europe SARL
Immeuble le Wilson
70 Avenue du General De Gaulle
Tel. +33 1477 39527
Review of designation
The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.
Documents related to this orphan designation evaluation
EU/3/14/1400: Public summary of opinion on orphan designation: (1S,4R,5R,7S)-3,4-dibenzyl-2-oxo-6,8-dioxa-3-azabyciclo[3.2.1]octane-7- carboxylic acid-L-lysine for the treatment of neurotrophic keratitis (PDF/118.06 KB)
First published: 26/02/2015
Last updated: 26/02/2015
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: